Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.
The data collected from the cut-off demonstrates that patients can maintain an average of 9.6 months without disease progression after the initial dosage of the tislelizumab-chemotherapy treatment.
To cope, life sciences companies are undertaking a supply chain risk assessment, conducting make-or-buy assessments, investing in supply chain technology and identifying backup suppliers.
Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.
Weeks after Imara announced its plans to discontinue the development of tovinontrinein for sickle cell and beta-thalassemia and heart failure, the company has culled 83% of its workforce.
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.